EXCLUSIVE: Uber Says It’s Making 3 Important Social Impacts With Weed Deliveries
With a mission to “be a go and get platform, to go anywhere and get anything,” Uber Eats’
EXCLUSIVE: Cannabis Industry Optimization Takes Center Stage As Hyper Growth Slows
Cannabis is "not a one-year thing," it's a "multi-decade growth opportunity," Aaron Grey, head of consumer research at A.G.P./Alliance Global Partners, told a full room of attendees gathered at the
INOVIO Announces Acceptance Of Abstract For Oral Presentation On INO-4201 As An Ebola Booster For rVSV-ZEBOV At ECCMID 2023
Immunological data from recently completed Phase 1b trial will be presented on April 16th
PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company
EXCLUSIVE: Cannabis Industry Experts Share Insights On Building Customer Loyalty – ‘It’s All About Education’
A panel of experts discussed how cannabis companies are targeting retail customers, at the Benzinga Cannabis Capital Conference in Miami Beach on Tuesday.
The panel shared tips and tricks on what businesses should be doing to engage and keep their customers coming back for more.
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data
EXCLUSIVE: Delivering Cannabis Is A Natural Extension For Uber, And Leafly Is Helping Navigate The Complex Road Ahead
Uber Eats teamed up with Leafly last year to deliver cannabis directly to the homes of customers in Canada, marking the first time cannabis delivery became available on a major third-party delivery platform.
EXCLUSIVE: How One Cannabis Company Is Blazing The Trail In ‘A Major Storm’
Even though capital markets in the cannabis industry are mostly dried up, there’s a way to still stay afloat, said Jason Wild, executive chairman of multistate state operator TerrAscend (OTCQX: TRSSF), and president and CIO of JW Asset Management.
IN8bio To Present New Clinical Data From Phase 1 Trial Of INB-100 At EBMT 2023 Annual Meeting
Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented; no dose-limiting toxicities have been observed
New correlative
Teva To Present New Data On Once-Daily AUSTEDO XR Extended-Release Tablets At The 2023 American Academy Of Neurology Annual Meeting
Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO®(deutetrabenazine) tablets
The U.S. Food and Drug Administration (FDA)
Reported Late Monday April 10, Foghorn Therapeutics To Present Preclinical Data From Its Selective CBP And EP300 Protein Degrader Programs And Preclinical Data For FHD-286, A Selective Inhibitor Of BRG1 And BRM At AACR April 14-19 2023
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that